•
Dec 31, 2019
Johnson & Johnson Q4 2019 Earnings Report
Johnson & Johnson reported strong sales and earnings growth in Q4 2019, driven by the Pharmaceutical business, accelerating performance in Medical Devices, and improved profitability in the Consumer business.
Key Takeaways
Johnson & Johnson announced its Q4 2019 results, reporting sales of $20.7 billion and EPS of $1.50. The company's performance was driven by its Pharmaceutical business, Medical Devices business, and Consumer business.
Q4 2019 sales reached $20.7 billion, reflecting a 1.7% growth.
Full-year sales for 2019 totaled $82.1 billion, a 0.6% increase.
Q4 2019 EPS was $1.50, a 33.9% increase, while adjusted EPS was $1.88, a 4.6% decrease.
The company projects continued sales and earnings growth in 2020.
Johnson & Johnson
Johnson & Johnson
Forward Guidance
Johnson & Johnson projects continued sales and earnings growth in 2020.
Positive Outlook
- Adjusted Operational Sales Change vs. Prior Year 5.0% - 6.0%
- Operational Sales Change vs. Prior Year $85.8 to $86.6
- Estimated Reported Sales Change vs. Prior Year $85.4 to $86.2
- Adjusted Operational EPS (Diluted) Change vs. Prior Year $9.00 to $9.15
- Adjusted EPS (Diluted) Change vs. Prior Year $8.95 to $9.10